SAN FRANCISCO, Aug. 20, 2025 /PRNewswire/ -- On August 15, 2025, shares in Soleno Therapeutics, Inc. (NASDAQ: SLNO) experienced a significant drop following the release of a highly critical report by Scorpion Capital. Hagens Berman, a national shareholders rights firm, has opened an...
Related Questions
How will the critical Scorpion report and ensuing lawsuit affect Soleno Therapeutics' short‑term stock volatility?
What potential financial exposure could arise from Hagens Berman’s shareholder rights action against SLNO?
Is there precedent for similar biotech legal challenges, and how did those companies' valuations recover over time?